Fig. 2From: Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practiceChanges of clinical findings from before to after short-acting exenatide over 20 weeks. (A) Hemoglobin A1c (HbA1c) level (n = 619), (B) Fasting plasma glucose (FPG) level (n = 54), (C) Body mass index (BMI) (n = 655), (D) Body weight (n = 674)Back to article page